Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
Intervention1: PSMA PET-CT: Prostate Specific Membrane Antigen PET-CT
Control Intervention1: Not Applicable: Not Applicable
Sponsors
AIIMS, Bhubaneswar
Eligibility
Inclusion criteria
Inclusion criteria: Patients with age more than18 years. Patients having past history of histologically proven glioma. Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy. Clinically suspected cases of recurrence. Patient should be willing to and able to give written informed consent
Exclusion criteria
Exclusion criteria: Pregnant lady. Breastfeeding mother. Patients who will deny to give consent. Any brain primary other than high grade glioma Patient diagnosed with other primary malignancy Patient with life threating neurological emergency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives 1. Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images 2. Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas 3. Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan 4. Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactGirish Kumar Parida
AIIMS, Bhubaneswar
Outcome results
None listed